NASDAQ · Biotechnology

MannKind Corporation (MNKD) Stock

$3.29 -3.80% NASDAQ: MNKD Healthcare

Valuation

MetricValue
Price$3.29
Market Cap$1.05B
P/E Ratio-24.73
P/B Ratio-15.87
P/S Ratio2.80
EPS (TTM)$0.02
52-Week High$6.51
52-Week Low$2.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE78.60%
ROA-5.96%
ROCE1.32%
Gross Margin75.96%
Operating Margin3.71%
Net Margin-11.08%
Debt/Equity-4.92
Current Ratio1.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$75.0M$100.0M$199.0M$286.0M$349.0M
Operating Profit$-47.0M$-64.0M$9.0M$73.0M$39.0M
Net Profit$-81.0M$-87.0M$-12.0M$28.0M$6.0M
EPS$-0.37$-0.44$-0.04$0.10$0.02
Op Margin-62.3%-64.3%4.4%25.4%11.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$321.0M$295.0M$475.0M$394.0M$792.0M
Total Liabilities$531.0M$546.0M$721.0M$473.0M$843.0M
Cash$124.0M$70.0M$238.0M$46.0M$75.0M
Borrowings$289.0M$288.0M$273.0M$48.0M$473.0M

Latest News

MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval Insider Monkey · Jul 9, 2026 MannKind (MNKD) Receives a Grant from Breakthrough T1D Insider Monkey · Jul 3, 2026 Is MannKind Corporation (MNKD) A Good Stock To Buy Now? Insider Monkey · Jun 29, 2026 MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D GlobeNewswire · Jun 23, 2026 Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” Insider Monkey · Jun 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-62.0M$-81.0M$34.0M$43.0M$18.0M
Investing Cash Flow$-163.0M$-3.0M$-44.0M$-106.0M$-309.0M
Financing Cash Flow$-13.0M$0$137.0M$2.0M$-9.0M
Net Cash Flow$57.0M$-54.0M$169.0M$-191.0M$29.0M
Free Cash Flow$-73.0M$-88.0M$-8.0M$33.0M$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.22
EV / EBITDA44.88
FCF Yield-1.69%
Quick Ratio1.41
Interest Coverage0.17
Return 1Y-5.12%
Return 3Y-12.19%
Return 5Y-13.00%

Ownership

Insiders Held1.55%
Institutions Held59.23%
Institutions Float Held60.16%
Institutional HolderSharesReport Date
Blackrock Inc.28,600,9982026-03-31
State Street Corporation18,683,4832026-03-31
Vanguard Capital Management LLC12,891,0662026-03-31
UBS Group AG8,255,4302026-03-31
Geode Capital Management, LLC7,505,1472026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About MannKind Corporation

MannKind Corporation is led by CEO Michael E. Castagna, employs 403 people, headquartered in US, publicly traded since 2004.

MannKind Corporation (MNKD) stock trades at $3.29 with a market capitalization of $1.05B. The stock is valued at a price-to-earnings (P/E) ratio of -24.73, price-to-book of -15.87, price-to-sales of 2.80. Over the past 52 weeks the stock has ranged between $2.23 and $6.51, and currently trades 49.5% below its 52-week high.

On profitability, MannKind Corporation generates a return on equity (ROE) of 78.60% — well above the market average, a sign of a high-quality business, return on capital employed of 1.32%, an operating margin of 3.71%, a net profit margin of -11.08%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides